THE TIME TO OFFER TREATMENTS FOR COVID-19
=========================================

* Binh T. Ngo
* Paul Marik
* Pierre Kory
* Leland Shapiro
* Raphael Thomadsen
* Jose Iglesias
* Stephen Ditmore
* Marc Rendell
* Joseph Varon
* Michael Dubé
* Neha Nanda
* Gino In
* Daniel Arkfeld
* Preet Chaudhary
* Vito M. Campese
* Diana L. Hanna
* David E. Sawcer
* Glenn Ehresmann
* David Peng
* Miroslaw Smogorewski
* April Armstrong
* Rajkumar Dasgupta
* Fred Sattler
* Denise Brennan-Rieder
* Cristina Mussini
* Oriol Mitja
* Vicente Soriano
* Nicolas Peschanski
* Gilles Hayem
* Marco Confalonieri
* Maria Carmela Piccirillo
* Antonio Lobo-Ferreira
* Iraldo Bello Rivero
* Eivind H. Vinjevoll
* Daniel Griffin
* Ivan FN Hung

## Abstract

**BACKGROUND** As of January 1, 2021, there have been 81,947,503 confirmed cases of COVID-19, resulting in 1,808,041 deaths worldwide. Several vaccines are now available for emergency use, but it will take many months to immunize the world’s population. There is a pressing need for outpatient treatment now. We reviewed the possible options

**METHODS** We reviewed up-to-date information from several sources to identify potential treatments to be utilized now for COVID-19. We searched for all ongoing, completed and published trial results with subject numbers of 100 or more, and used a targeted search to find announcements of unpublished trial results.

**RESULTS** As of December 27, 2020, we identified 750 trials currently in recruitment phase. Of these, 122 were directed at prevention in healthy individuals, 100 were classified as treatment of outpatients with documented infection, and 390 were for treatment of hospitalized inpatients. There were 9 trials focusing on the post discharge Tail phase. Among the trials, there were 60 vaccine trials, 120 trials of hydroxychloroquine, 33 trials of alternative therapy, 12 trials of colchicine, 38 trials of anticoagulants, 22 trials of the RNA polymerase inhibitor favipiravir (FVP), 19 trials of interferons, 18 trials of glucocorticoid, and 58 trials of plasma based products. Closure of enrollment was projected by the end of the year for 153 trials. We found 83 publications reporting findings in human studies on 14 classes of agents, and on 7 vaccines. There were 45 randomized or active controlled studies, the rest retrospective observational analyses. Most publications dealt with hospitalized patients, only 18 publications in outpatients. Remdesivir, convalescent plasma, and synthetic anti-spike protein antibodies have been granted emergency use authorization in the United States. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. There is data supporting the use of several antiviral medications, some of which are in use in other countries.

**CONCLUSION** Vaccines and antibodies are highly antigen specific. There is a need for antiviral agents in addition to mass immunization. It will be necessary for public health authorities to make hard decisions, with limited data, to prevent the continued spread of the disease and deaths.

## 1. INTRODUCTION

SARS-Cov-2 spread with extraordinary speed from its origin in December 2019 in Wuhan, China. As of January 1, 2021, there have been 81,947,503 confirmed cases of COVID-19, resulting in 1,808,041 deaths worldwide affecting 220 countries and territories (1). Symptomatic COVID-19 exhibits a characteristic sequence of phases related to the primary viral attack, manifesting as an influenza-like illness, affecting 80% of infected individuals. Then, in patients destined for severe disease, within seven to 10 days of onset of symptoms, an organizing pneumonia develops which requires assisted mechanical ventilation in up to 5% of patients (See Figure 1) (2, 3). Elevated cytokines and a coagulopathy at this pulmonary stage suggests an immune reaction as probable cause (4, 5).

![Figure 1:](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2021/01/23/2020.05.27.20115238/F1.medium.gif)

[Figure 1:](http://medrxiv.org/content/early/2021/01/23/2020.05.27.20115238/F1)

Figure 1: 
THE PHASES OF COVID-19 INFECTION. Asymptomatic viremia typically lasts for 5 days followed by symptoms of an upper respiratory infection. The immune response takes hold over the next week. Pneumonic infiltrates begin to appear. In patients destined for severe infection, a hyperinflammatory reaction takes hold, leading to worsening of pulmonary symptoms, hypoxia, and potentially acute respiratory distress syndrome.

In mainland China, vigorous efforts to contain the spread of COVID-19 by home isolation, closure of business activity, travel bans, and tracking and control of contacts succeeded. As of December 10, China has had 96,762 confirmed cases and 4,789 deaths, but the number of new cases has been low since April (1). Similar measures contained the epidemic in Taiwan and in New Zealand (1). However, the disease has not been controlled in the rest of the World, particularly Europe where there have been 26,490,355 cases with 582,016 deaths and the United States (USA) where, despite only a fifth of the population of China, there have been 19,746,390 confirmed cases of COVID-19 and 335,789 deaths. (1). In the Western World, as in China, the response to the pandemic was through reduction of person-to-person contact. Beginning in early March, social gatherings and meetings ended; schools and businesses were closed along with recreation areas, parks, and beaches. These social distancing efforts blunted the spread of the disease, but not with the results achieved in China. Due to economic pressures, epidemiologic containment was relaxed resulting in a significant ongoing surge well surpassing the original April peak.

The major industrialized countries have made an unprecedented effort to rapidly develop vaccines for COVID-19. Two mRNA vaccines have demonstrated 90% effectiveness at two months post immunization, and mass vaccination has begun. However, in view of the continuing daily increase in new cases and deaths, we believe that it is unwise to place sole reliance on immunization alone. Our goal was to assess the options at the present time for release of pharmacologic agents to treat and to prevent COVID-19 while pursuing widespread vaccination in 2021.

## 2. METHODS

### 2.1 CLINICAL TRIALS

We reviewed up-to-date information from multiple sources to identify potential treatments for COVID-19: The Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub was used to track the efforts of companies to develop therapeutic interventions. We searched for investigational trials in active recruitment and those that have completed enrollment. We used (A) covid-trials.org, a registry to collate all trials in real time with data pulled from the International Clinical Trials Registry Platform and all major national registries (6). We cross validated information on (B) clinicaltrials.gov, the registry of clinical trials information maintained by the United States National Library of Medicine. We further cross referenced the trials on C) the World Health Organization’s International Clinical Trials Registry Platform (WHO ICTRP), and (D) (Cochrane COVID-19 Study Register. We excluded studies which were clearly observational with multiple different treatments, with no means of comparison. We further set a cutoff of 100 for numbers of subjects since smaller trial size typically lacks statistical power to enable regulatory approval. For each trial selected, we documented the setting of patient contact, either hospital or outpatient, the type of control procedure, the date the trial was initially registered, and the proposed date of completion of enrollment.

### 2.2 PUBLISHED TRIAL RESULTS

Our search was carried on the week of December 27, 2020. We identified all publications on pubmed.gov to find peer reviewed articles, on medRxiv to find preprint reports and the WHO Global Literature on Coronavirus Disease. We further carried out daily Google™ searches on each potential treatment to find preliminary reports, typically presented as press releases, reviewed by a journalist. We included all publications in our results as well as trial results posted as complete on Clinicaltrials.gov. We did not exclude trials with less than 100 subjects, since many reports were interim, with trials ongoing.

### 2.3 VIRTUAL DISCUSSIONS AMONG CO-AUTHORS

We used the preprint server medRxiv to post a systematic analysis of the development of therapeutic interventions for COVID-19 in order to stimulate diffusion of the manuscript and allow widespread “open source” input from co-authors (7). Successive versions of the preprint article have been posted periodically as a chronicle beginning in late May, 2020 and continuing to date (8). This process led to the present multinational consensus process involving 36 co-authors.

## 3. RESULTS

### 3.1 REVIEW OF CURRENT TRIALS

As of December 27, 2020, we identified 750 trials currently in recruitment phase with subject size of 100 or more (Supplementary Table 1). Of these, 122 were directed at prevention in healthy individuals, 100 were classified as treatment of outpatients with documented infection, and 390 were for treatment of hospitalized inpatients. There were 9 trials focusing on the post discharge Tail phase. The remaining trials were unclear as to intended subjects. Among the trials, there were 60 vaccine trials, 120 trials of hydroxychloroquine (HCQ), 33 trials of alternative therapy, 12 trials of colchicine, 38 trials of anticoagulants, 22 trials of the RNA polymerase inhibitor favipiravir (FVP), 19 trials of interferons, 18 trials of glucocorticoid, and 58 trials of plasma based products. Closure of enrollment was projected by the end of the year for 153 trials.

View this table:
[Table2](http://medrxiv.org/content/early/2021/01/23/2020.05.27.20115238/T2)

### 3.2 COMPLETED TRIALS

As of December 27, 2020, there were 97 trials reporting completion with 100 or more subjects(Supplementary Table 2 There were 52 trials in hospitalized patients, 9 directed at outpatients, and 12 prevention studies, the rest mixed.

View this table:
[SUPPLEMENTARY TABLE 2:](http://medrxiv.org/content/early/2021/01/23/2020.05.27.20115238/T3)

SUPPLEMENTARY TABLE 2: 
TRIALS COMPLETED AS OF December 27, 2020. The registration ID for the respective regulatory body is given along with the country of registration and the date of completed enrolment. The setting for subjects in each trial: HOSP: Hospitalized; PREV: Healthy or exposed volunteers; OUTPAT: Infected patients, not hospitalized; UNCLEAR: Including multiple categories. SOC: Standard of Care.; FPV: Favipiravir; LPV/R: lopanovir/ritonavir; HCQ: hydroxychloroquine; AZM: azithromycin; TCM: A Chinese herbal tea; NSAID: Non-steroidal anti-inflammatory drug; Conv Plasma: Convalescent plasma

### 3.3 PUBLISHED RESULTS ON COVID-19 TRIALS

As of December 27, 2020 we found 83 publications reporting findings in human studies on 14 classes of agents, and on 7 vaccines (See TABLE 1). There were 45 randomized or active controlled studies. The rest were retrospective observational analyses. Only 15 publications dealt with outpatient care, including 7 vaccine reports; the rest were all in hospitalized patients.

View this table:
[TABLE 1.](http://medrxiv.org/content/early/2021/01/23/2020.05.27.20115238/T1)

TABLE 1. 
PUBLISHED STUDIES AS OF DECEMBER 27, 2020. Each agent is listed along with the country originating the publication. We have listed studies with 100 or more subjects. The type of control procedure: RCT: Randomized controlled study PLAC: Placebo, soc: standard of care which is variable depending on each location. AC: Active control: the control options are listed in parenthesis. OBS: retrospective observation study. LPV/R: lopanovir/ritonavir; HCQ: hydroxychloroquine; AZM: azithromycin; IFN: interferon; tocilizumab: TCZ. SEV: severe; CRIT: critical; MOD: moderate. W.H.O.: World Health Organization

**3.3.1** In the group of antiviral agents, the largest published randomized, controlled trials were with the intravenously administered RNA polymerase inhibitor remdesivir (9–13). A double blind, randomized placebo controlled trial of remdesivir, in 1062 moderate to severely ill patients was carried out by the National Institute of Allergy and Infectious Disease (NIAID) (10). The patients who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001). P<0.001). The Kaplan-Meier estimates of mortality by 29 days after randomization were 11.4% with remdesivir and 15.2% with placebo (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). On the basis of this trial, the Food and Drug Administration (FDA) approved the use of remdesivir for COVID-19 hospitalized patients. A different study of remdesivir in hospitalized patients with moderate COVID-19 clinical status showed improved clinical status by day 11 compared to standard of care for a 5 day course of remdesivir, but not for a 10 day course (12). There has been no data provided on viral clearance for the U.S. remdesivir studies. In early April, the WHO organized a megatrial, appropriately named Solidarity, to assess four separate treatment options only in hospitalized patients: (a) Remdesivir, an intravenously administered inhibitor of RNA polymerase; (b) The HIV agent lopanovir/ritanovir (LPV/R); (c) LPV/R plus Interferon β-1a; and (d) the antimalarials hydroxychloroquine (HCQ) and chloroquine (13). Results of the Solidarity Trial were reported by the World Health Organization on October 15, 2020. They found no effect of remdesivir on 28 day mortality, need for mechanical ventilation nor duration of hospitalization in a study including 5451 hospitalized patients (13).

**3.3.2** There were two positive randomized, active control clinical trials in China of the orally administered RNA polymerase inhibitor favipiravir (FVP) (14, 15). In a trial comparing 116 patients on FVP to 120 on umifenovir, the 7 day clinical recovery rate was 55.9% for the umifenovir group and 71% in the FVP group (15). In Russia, a preliminary study of FVP showed reduced duration of viral shedding, and the drug was approved for clinical treatment beginning in multiple hospitals on June 12, 2020 (17). In a follow-up phase 3 study, they reported 27% clinical improvement at day 10 compared to 15% for standard care with 98% clearance of SARS-COV-2 compared to 79% (18). In India, a study of 150 mild to moderate COVID-19 patients showed median time to clinical cure of 3 days (95% CI: 3 days, 4 days) for FVP versus 5 days (95% CI: 4 days, 6 days) for control, P=0.030, and FVP was approved to treat COVID-19 in July (19). In late September, a report, still unpublished, of a randomized controlled study in Japan announced more rapid viral clearance in FVP treated patients.

**3.3.3** There have been many studies of HCQ (20–47). A group in Marseille reported their experience with 3737 patients screened positive for SARS-Cov-2 and immediately treated with HCQ and azithromycin (AZM), after excluding patients at risk of QT prolongation (20). They showed clearance of viral shedding in 89.4% of the patients by ten days. The overall mortality in their population was 0.9%, none in patients under 60 years old, and no sudden cardiac deaths. They had no randomized control population, but their study prompted immediate widespread use of HCQ throughout the world for treatment of COVID-19 patients.

Subsequent randomized controlled studies in hospitalized patients have shown no clinical nor mortality benefit of HCQ. In the randomized RECOVERY trial in 1542 hospitalized patients in the United Kingdom, there was no significant difference in the primary endpoint of 28-day mortality (26.8% HCQ vs. 25% usual care; hazard ratio 1.09 [95% confidence interval 0.96-1.23]; *p*=0.18) (34). In the Solidarity Trial, there was no benefit of HCQ on mortality (HCQ RR=1.19 (0.89-1.59, p=0.23; 104/947 vs 84/906), need for mechanical ventilation, nor duration of hospitalization (13). However, in a retrospective comparison study at NYU Langone Health for all patients admitted between March 2 and April 5, 2020, there was a move to add zinc 100 mg daily to their standard HCQ plus AZM regimen (35). There was a significantly lower mortality (13.1%) among the zinc treated patients compared to those who did not receive zinc (22.8%).

There has been limited study of HCQ in outpatients. In one internet-based prevention study, with HCQ given for 5 days to healthy individuals with a significant exposure to SARS-Cov-2, the incidence of new illness compatible with COVID-19 did not differ significantly between participants receiving HCQ (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); absolute difference −2.4 percentage points (95% confidence interval, −7.0 to 2.2; *p*=0.35) (36). The same group also treated 423 patients with mild symptoms imputed to COVID-19 (37). At 14 days, 24% (49 of 201) of participants receiving HCQ had ongoing symptoms compared with 30% (59 of 194) receiving placebo (*p* = 0.21).

A study in Spain of 293 patients with PCR-confirmed mild COVID-19, found no difference in viral load nor risk of hospitalization following 6 days of HCQ treatment compared to untreated patients (38). The same group treated 1,116 healthy contacts of 672 Covid-19 index cases with HCQ while 1,198 were randomly allocated to usual care (39). There was no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ).

A large population study in Portugal surveyed all patients on chronic HCQ treatment and cross-verified against a mandatory database of patients registered with COVID-19 (40). The incidence of a positive PCR test for SARS-CoV-2 infection in patients receiving HCQ was 5.96%, compared to 7.45% in those not so treated, adjusted odds ratio 0.51 (0.37-0.70). However, two separate randomized controlled studies found no evidence of benefit of two months prophylactic treatment of hospital workers with HCQ (41, 42).

**3.3.4**. Published results with Lopanovir/ritonavir (LPV/r) have been disappointing (13, 43–45). In a randomized trial with 99 patients on LPV/r and 100 receiving standard care, there was no difference in time to clinical improvement, mortality nor viral clearance (44). In the RECOVERY trial in 1,596 hospitalized patients there was no significant difference in the primary endpoint of 28-day mortality (22.1% LPV/r vs. 21.3% usual care; relative risk 1.04 [95% confidence interval 0.91-1.18]; (*p*=0.58) (45). In the Solidarity Study, there was no effect of LPV/r on 28 day mortality LPV/r RR=1.00 (0.79-1.25, p=0.97; 148/1399 vs 146/1372), need for mechanical ventilation nor duration of hospitalization (13).

A possibly more favorable result was obtained in Hong Kong in a study of 86 patients assigned to triple combination therapy with LPV/r plus ribavirin plus interferon β-1 (46). Compared to a control group of 41 patients receiving LPV/r alone, the combination group had a significantly shorter median time from start of study treatment to negative SARS-Cov-2 nasopharyngeal swab (7 days [IQR 5–11]) than the control group (12 days [8– 15]; hazard ratio 4.37 [95% CI 1.86–10.24], *p*=0·0010). The time to complete alleviation of symptoms was 4 days [IQR 3–8] in the combination group vs 8 days [7–9] in the control group; HR 3.92 [95% CI 1.66–9.23. This study was interpreted not as supporting LPV/r therapy, but rather focusing on interferon β-1 as the primary treatment modality.

**3.3.5** Interferon studies have been encouraging. In Cuba, a combination of interferon-α-2b and interferon γ on background therapy of LPV/r and chloroquine was successful in achieving viral clearance in 4 days in 78.6% of the patients compared to 40.6% of those receiving interferon-α-2b alone (49). In the Solidarity Study in hospitalized patients, there was no effect of injected interferon on 28 day mortality (IFN RR=1.16 (0.96-1.39, p=0.11; 243/2050 vs 216/2050), need for mechanical ventilation nor duration of hospitalization (13). However, a separate trial of nebulized interferon β-1 reported positive improvement in clinical status (52).

**3.3.6** There have been many observational studies of immunomodulatory therapy with the IL-6 inhibitor tocilizumab and the IL-1 inhibitor anakinra to mitigate the pulmonary phase of COVID-19 suggesting reduction of mortality and need for intubation in hospitalized severe and critically ill patients (28, 53–66). However, in several randomized control studies, there has been no benefit with tocilizumab (67–69). In the COVACTA trial, there was no benefit of tocilizumab in clinical status, mortality (19.7% tocilizumab vs placebo = 19.4%), nor in ventilator free days (68), and in the Cor-Immuno-Toci trial, no decrease in mortality at day 28 (69). The tocilizumab results in these randomized controlled trials were affected by a higher frequency of glucocorticoid use in the control groups.

**3.3.7** Pre-COVID-19, glucocorticoid treatment had been a recognized treatment with mortality benefit for patients in severe respiratory distress (70). Dexamethasone has now demonstrated benefit in several COVID-19 hospital trials (71–72). In the RECOVERY trial, 2104 patients were randomly allocated to receive dexamethasone for ten days compared to 4321 patients concurrently allocated to usual care (72). Overall, 454 (21.6%) patients randomized to dexamethasone and 1065 (24.6%) patients receiving usual care died within 28 days (age adjusted rate ratio [RR] 0.83; 95% confidence interval [CI] 0.74 to 0.92; *p*<0.001). Dexamethasone reduced deaths by one-third in the subgroup of patients receiving invasive mechanical ventilation (29.0% vs. 40.7%, RR 0.65 [95% CI 0.51 to 0.82]; *p*<0.001) and by one-fifth in patients receiving oxygen without invasive mechanical ventilation (21.5% vs. 25.0%, RR 0.80 [95% CI 0.70 to 0.92]; *p=*0.002), but did not reduce mortality in patients not receiving respiratory support at randomization (17.0% vs.13.2%, RR 1.22 [95% CI 0.93 to 1.61]; *p*=0.14). Most trials of other glucocorticoids have shown similar benefits in COVID-19 patients with acute respiratory failure (73–80)

**3.3.8** There is promising data on convalescent plasma (81–86). A meta-analysis including 4173 patient outcomes across a multinational series of studies concluded that convalescent plasma treatment yielded a 57% reduction in mortality (85). The reduction was greatest in patients treated within 3 days of diagnosis with high titer antibody plasma. Based on evidence of safety in over 20,000 patients in an expanded access program coordinated by the Mayo Clinic, the U.S. FDA recently issued an emergency authorization for use of convalescent plasma (86). Monoclonal antibodies to the SARS-COV-2 spike protein have been synthesized. Treatment of ambulatory patients with the LY-CoV555 neutralizing antibody and the Regeneron combination of two antibodies early in the course of infection has shown success in reducing the frequency of hospitalization, and the FDA issued an emergency authorization for use in outpatients (88).

**3.3.9** There have been a number of reports on agents not ordinarily considered as antivirals. These include famotidine, nitazoxanide, fluvoxamine, colchicine, and ivermectin (89–96). Colchicine, an anti-inflammatory agent, suggested benefit in the GRECCO, placebo-controlled, randomized clinical trial of 105 patients (90). The primary clinical end point of deterioration to mechanical ventilation or death was 14% in the control group (7 of 50 patients) and 1.8% in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95% CI, 0.01-0.96; p = 0.02). There have now been a number of trials including several randomized controlled studies suggesting benefit with ivermectin both in prevention and in treatment of COVID-19 (TABLE 1).

**3.3.10** A number of vaccines have reported successful induction of neutralizing antibody and cellular immune responses in early phase trials (98–104). The Moderna and Pfizer Biontech mRNA spike protein vaccines released data showing over 90% effectiveness at preventing symptomatic infection in a 2 month post immunization observation period, and emergency authorization for immunization has been given. Massive vaccinations have begun in many countries.

## 4. CONCLUSION

SARS-Cov-2 fueled by modern day jet travel overwhelmed medical preparedness for the pandemic. Current projections are for a continuation of new cases and deaths continuing in 2021 (105, 106). On December 31, 2020, 470,046 new cases were reported worldwide (1). Of these 174, 814 cases occurred in the United States. Clinical trials to date have focused primarily on hospitalized patients to try to prevent death. It is hoped that the use of remdesivir, convalescent plasma, glucocorticoids, anticoagulation and improved management of COVID-19 respiratory failure will lower the present rate of in hospital mortality which in some series has been as low as 6% but in most hospitals still approaches 20% (77). However, it is essential to change the present dynamic of attempted therapeutic responses to recognize specific phases of the disease (107). In particular, efforts must now focus on prevention and treatment of the initial viral infection so that hospitalization can be avoided. We face a dilemma with inadequate current prevention and treatment for outpatients with mild to moderate disease, constituting 80% of the infected population and the primary mode of spread of SARS-Cov-2. The lessons learned in very sick hospitalized patients do not necessarily apply to the earlier viremic phase. Antiviral agents, such as remdesivir and favipiravir, interferon, convalescent plasma, and monoclonal antibodies are likely to be most effective during the early stage of viremia, which is prior to the pulmonary phase requiring hospitalization.

Vaccines have been the solitary hope held out by public health authorities to arrest SARS-Cov-2. Progress on vaccine development has been rapid, but the speed of development does not reduce the challenges of developing vaccines to be administered to the population of the entire World. Although neutralizing antibodies and memory T cells can be produced by the vaccine candidate, the demonstration of true protection requires long-term follow-up of an exposed vaccinated population. The current vaccines will be released for emergency use after only a short two month period of observation. No matter how rapidly a vaccine advances to Phase III testing, the duration of follow-up cannot be shortened, and for SARS-Cov-2 possibly prolonged due to several factors. First, there is a risk of immune enhancement of infection which occurs when induced antibodies increase entry and internalization of virus into myeloid cells (108). This major complication struck the newly developed dengue vaccine in 2017 (109). Second, the sinister autoimmune pathogenicity of SARS-Cov-2 raises the risk of delayed long-term harm if the virus is not fully and immediately eradicated by the initial immune response to the vaccine. Furthermore, studies of recurrent coronavirus infections suggest that infection may confer immunity for less than a year (110). After implementation of a new vaccine, efforts to find volunteers for trials of new, more effective vaccines will be hampered if there is no treatment available for placebo treated patients who become infected. Vaccines are specific to the intended pathogen. There is the risk that the virus will mutate to a form for which the new vaccine may not be fully protective. Already two variants have emerged and caused major outbreaks. The level of protection offered by the current vaccines is currently under study. Finally, the degree of acceptance of the COVID-19 vaccines by the general population is questionable. Seasonal influenza vaccination coverage was only 48% in 2019 (111). Children typically have limited COVID-19 symptoms. However, they may serve as a reservoir of ongoing infectivity (112). Currently there have been no clinical trial results of vaccine in children.

It also follows that totally new viruses may emerge just as did SARS-Cov-2. COVID-19 is now the sixth severe viral epidemic to hit mankind in the past 20 years; certainly it has been more widespread than SARS-Cov-1, H1N1 influenza, MERS, Zika, and Ebola, but that does not diminish the gravity of these repeated viral threats. Development of antigen specific vaccines takes a long time during which disease takes a large toll as has been the case for SARS-Cov-2. The succession of viral afflictions points to the need to implement widespread use of antiviral agents. The current recom-mendation for COVID-19 is home quarantine with no specific treatment for patients with suspicious symptoms. What is needed is therapeutic intervention which can be used to treat all outpatients with positive COVID-19 tests at the time of initial symptoms, not waiting for deterioration requiring hospital care. Hydroxychloroquine has not succeeded. Remdesivir administered intravenously for five days is not a practical daily outpatient treatment; Gilead© is attempting to develop an inhaled remdesivir formulation, but those efforts are only now beginning. Favipiravir, a tablet, could be used in early stages of infection and has now been released in Russia, Hungary, and in India, but not in the United States and the European Union. It has known embryogenic risks, so its use requires restrictions on women of childbearing potential, as is the case with tretinoin for acne and thalidomide for multiple myeloma. Trials with camostat, the serine protease inhibitor, capable of blocking cell entry of SARS-Cov-2, are not due to end till the fourth quarter of the year. Similarly, a prevention trial with colchicine is not scheduled to end until the fourth quarter of 2020. Convalescent plasma is used primarily in hospital patients. Monoclonal antiviral neutralizing antibodies based on the same principle have finally received emergency use authorization for ambulatory patients. However, the scale of production of these monoclonal antibodies is far too limited to offer to all outpatients who should be treated. Interferon formulations have shown promise in several studies. There have been several randomized controlled studies suggesting benefit with ivermectin both for prophylaxis and treatment.

Yet, at this time, no outpatient therapy has been proven safe and effective in large scale phase III randomized, placebo-controlled studies. There are strong arguments to avoid emergency use of agents until trials are completed and analyzed, but the agents suggested are not new. Most are drugs like ivermectin, colchicine, and the interferons, marketed and available for other conditions and with well-known safety profiles. There is a clear need to offer outpatient therapeutic intervention now to the World’s population.

There is a precedent to resolve the conflict between immediate clinical need and the requirements for rigorous controlled trials to prove efficacy. We should remember that the greatest success in fighting a pandemic occurred over the past two decades in the battle against the HIV virus which causes AIDS. AIDS was first recognized in 1981 in the MSM (men who have sex with men) community. The disease was considered a death sentence.

There was widespread fear because there was no treatment, and projections of infection escalated into the millions. The first AIDS remedy was azidothymidine (AZT), synthesized in 1964 in the hope that it would combat cancer. Twenty years later Dr. Samuel Broder, head of the National Cancer Institute, showed that the drug had activity against the HIV virus in vitro (113). Burroughs Wellcome launched a rapidly conceived trial with just 300 patients. They stopped the trial in 16 weeks claiming that more patients survived on AZT. The FDA came under enormous pressure from AIDS activists to make the drug available, and it was approved on March 19, 1987, with only that one trial. It had taken 20 months for the FDA to give approval to release the drug. To this day, the design and results of the trial remain controversial.

The LGBT community continued to battle for early release of other medications to combat the AIDS pandemic. On October 11, 1988, a massive protest occurred at the FDA. It was back then Dr. Anthony Fauci who publicly advanced the idea of a parallel track to make drugs widely available even while studies are progressing: “*Clearly, the standard approach to the design of clinical trials—that is, rigid eligibility criteria as well as the strict regulatory aspects that attend clinical trial investigations and drug approval—was not well-suited to a novel, largely fatal disease such as this with no effective treatments, and we had many intense discussions about how to make that approach more flexible and ethically sound*. *One example, which I and others worked closely with the AIDS activists to develop, was called a parallel track for clinical trials. The parallel track concept, which the United States Food and Drug Administration ultimately came to support, meant that there would be the standard type of highly controlled admission criteria and data collection for the clinical trial of a particular drug. In parallel, however, the drug also could be made available to those who did not meet the trial’s strict admission criteria but were still in dire need of any potentially effective intervention, however unproven, for this deadly disease*” (114).

The parallel track advocated by Dr. Fauci was adopted. Today, there are 41 drugs or combinations approved by the FDA to treat and to prevent HIV infection. There is still no vaccine. There are now an estimated 1.1 million patients with HIV in the United States, most enjoying near normal life expectancy thanks to the antiviral agents. The CDC has contributed greatly to limit the spread of HIV by advocating safe sex practices, but social distancing is not the norm for HIV. Rather “treatment as prevention” for people with HIV using highly active antiretroviral regimens to prevent transmission as well as pre-exposure prophylaxis with a daily antiviral combination pill are currently endorsed by the CDC and adopted in wide segments of the at risk population (115).

In this pandemic crisis, we appeal to public health authorities to change the dynamic of current studies to outpatient care and to cross institutional, commercial and international boundaries to collate and combine all randomized controlled data submitted for all agents in Europe, China, Russia, Japan, India and other countries, and by competing companies, whether officially published, posted on line, or unpublished to finalize confirmatory results. The Solidarity Trial is a model of what could and should be done to unify a worldwide effort to pursue randomized controlled studies in outpatients. At the same time, agents with favorable preliminary results and no safety issues should be made available through a parallel track. In Russia and India, the parallel track has been fully implemented, with FVP now offered as treatment throughout both countries, even as further confirmatory controlled trials proceed. Interferon formulations are now approved treatments in China and Cuba. It is reasonable to authorize vaccination in very large parallel track studies in at risk populations, such as healthcare workers and the elderly. At this time, with no other option available, vaccination will have to be universal, despite the need to perform controlled studies to develop improved vaccines. However, it is unwise to rely solely on the hope for eventual mass vaccination to stop SARS-Cov2. Antiviral medication has succeeded in limiting HIV and hepatitis, and antivirals are just as important as annual vaccination for control of influenza. It is necessary for public health authorities to make hard decisions now despite limited current data and offer outpatient treatments on a broad front with no further delay.

## Data Availability

We have provided a comprehensive list of all clinical trials with their registration as Supplementary Table 1 and all completed trials as Supplementary Table 2

[https://www.covid-trials.org/](https://www.covid-trials.org/) 

[https://clinicaltrials.gov/](https://clinicaltrials.gov/) 

[https://www.who.int/ictrp/en/](https://www.who.int/ictrp/en/) 

[https://reaganudall.org/covid-19](https://reaganudall.org/covid-19) 

## Footnotes

*   1 From the Keck Medical School of USC

*   2 From the Rose Salter Medical Research Foundation

*   3 CoSenior author

*   mdube{at}med.usc.edu, Neha.nanda{at}med.usc.edu, Gino.In{at}med.usc.edu, arkfeld{at}med.usc.edu, Preet.chaudhary{at}med.usc.edu, campese{at}med.usc.edu, Diana.Hanna{at}med.usc.edu, David.sawcer{at}med.usc.edu, Glenn.ehresmann{at}med.usc.edu, David.Peng{at}med.usc.edu, smogorze{at}med.usc.edu, April.armstrong{at}med.usc.edu, ‘Dasgupta, Rajkumar’ rdasgupt{at}med.usc.edu, fsattler{at}usc.edu

*   updated as of January 1, 2021

*   Received May 27, 2020.
*   Revision received January 21, 2021.
*   Accepted January 23, 2021.


*   © 2021, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## REFERENCES

1.  1).WHO Coronavirus Disease (COVID-19) Dashboard Data last updated: 2021 January 1 11 am.
    
    

2.  2).Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239–1242
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.2648&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

3.  3).Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE4OiIzNjgvbWFyMjZfMTAvbTEwOTEiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8wMS8yMy8yMDIwLjA1LjI3LjIwMTE1MjM4LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

4.  4).Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020 Apr 17 [https://doi.org/10.1111/jth.14849](https://doi.org/10.1111/jth.14849).
    
    

5.  5).Ricardo J, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation storm: Lancet Respir Med 2020; 8(6): e46–e47
    
    

6.  6).Thorlund KT, Dron L, Park J et al. A real-time dashboard of clinical trials for COVID-19. Lancet Digital Health 2020; 2: e86–e87 published on line 24 Apr 20 [https://doi.org/10.1016/S2589-7500(20)30086-8](https://doi.org/10.1016/S2589-7500(20)30086-8)
    
    

7.  7).Ngo BT, Rendell M. A systematic analysis of the time course to develop treatments for COVID-19 medRxiv 2020.05.27.20115238; doi: [https://doi.org/10.1101/2020.05.27.20115238](https://doi.org/10.1101/2020.05.27.20115238)
    
    

8.  8).Ngo BT, Marik P, Kory P, et al. The time to offer treatments for COVID-19. medRxiv, 16 Dec20 doi: [https://doi.org/10.1101/2020.05.27.20115238](https://doi.org/10.1101/2020.05.27.20115238)
    
    

9.  9).Wang Y, Zhang D, Guanhua Du G, et al. Remdesivir in adults with severe COVID-19: a randomised,double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395 (10236): 1569–1578
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)31022-9&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

10. 10).Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 — final Report. October 8, 2020 DOI: 10.1056/NEJMoa2007764
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2007764&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32445440&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

11. 11).Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. New Engl J Med May 27, 2020 DOI: 10.1056/NEJMoa2015301
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2015301&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32459919&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

12. 12).Spinner CD, Gottlieb RL, Criner GJ et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. A randomized clinical trial. JAMA. Published online August 21, 2020. doi:10.1001/jama.2020.16349
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.16349&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32821939&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

13. 13).WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv 2020.. [https://doi.org/10.1101/2020.10.15.20209817](https://doi.org/10.1101/2020.10.15.20209817) posted Oct 15, 2020
    
    

14. 14).Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study Engineering (Beijing). 2020;10.1016/j.eng.2020.03.007. doi:10.1016/j.eng.2020.03.007
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.eng.2020.03.007&link_type=DOI) 

15. 15).Chen C, Huang J, Zhenshun Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: A randomized clinical trial. medRxiv preprint doi: [https://doi.org/10.1101/2020.03.17.20037432](https://doi.org/10.1101/2020.03.17.20037432).this version posted March 20, 2020.
    
    

16. 16).Preliminary Report of the Favipiravir Observational Study in Japan Favipiravir Observational Study Group. [http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19\_casereport\_en\_200529.pdf](http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf) Accessed 3.19 June 2020
    
    

17. 17).Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a Phase II/III multicenter randomized clinical trial. Clinical Infectious Diseases, ciaa1176, [https://doi.org/10.1093/cid/ciaa1176](https://doi.org/10.1093/cid/ciaa1176)
    
    

18. 18).[https://clinicaltrials.gov/ct2/show/NCT04542694](https://clinicaltrials.gov/ct2/show/NCT04542694): Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19. Results posted 9 Nov 2020
    
    

19. 19).Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized,comparative, open-label, multicenter, phase 3 clinical trial. Int J Infec Disease (In Press)
    
    

20. 20).Lagier JC, Million M, Gautret P, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis. 2020 July-August; 36: 101791.. Available on line 25 June 2020
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.tmaid.2020.101791&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32593867&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

21. 21).Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv preprint doi:[https://doi.org/10.1101/2020.03.22.20040758](https://doi.org/10.1101/2020.03.22.20040758). this version posted March 30, 2020.
    
    

22. 22).Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) J Zhejiang Univ (Med Sci) 2020, Vol. 49 Issue (1): – DOI: 10.3785/j.issn.1008-9292.2020.03.03
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3785/j.issn.1008-9292.2020.03.03&link_type=DOI) 

23. 23).Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. BMJ 2020;369:m1849
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNjkvbWF5MTRfNS9tMTg0OSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAxLzIzLzIwMjAuMDUuMjcuMjAxMTUyMzguYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

24. 24).Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. Med (2020), [https://doi.org/10.1016/j.medj.2020.06.001](https://doi.org/10.1016/j.medj.2020.06.001)
    
    

25. 25).Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. New Engl J Med 2020 ;382(25):2411–2418
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

26. 26).Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020; 323(24): 2493–2502.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

27. 27).Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:m1844
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNjkvbWF5MTRfNy9tMTg0NCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAxLzIzLzIwMjAuMDUuMjcuMjAxMTUyMzguYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

28. 28).Ip A, Berry DA, Hansen E, et al., Hydroxychloroquine and tocilizumab therapy in COVID-19 patients - An observational study. PLoS ONE 15(8): e0237693.
    
    

29. 29).Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Inf Dis. 2020 ; 97: 396–403
    
    

30. 30).Cavalcanti AB. Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New Eng J Med published on line July 23, 2020 DOI: 10.1056/NEJMoa2019014
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2019014&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32706953&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

31. 31).Furtado RHM, Berwanger O*, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet 2020; 396: 959–67
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)31862-6&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32896292&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

32. 32).Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial. JAMA Netw Open. 2020 Apr 24;3e208857. doi: 10.1001/jamanetworkopen.2020.8857,
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jamanetworkopen.2020.8857&link_type=DOI) 

33. 33).Self WH, Semler MW, Leither LM, et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19 A randomized clinical trial JAMA. Published online November 9, 2020. doi:10.1001/jama.2020.22240
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.22240&link_type=DOI) 

34. 34).RECOVERY Collaborative Group. Effect of Hydroxychloroquine in hospitalized patients with COVID-19. New Engl J Med October 8, 2020 DOI: 10.1056/NEJMoa2022926
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2022926&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33031652&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

35. 35).Carlucci P, Tania Ahuja T, Petrilli CM, et al. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients medRxiv doi: [https://doi.org/10.1101/2020.05.02.20080036](https://doi.org/10.1101/2020.05.02.20080036)
    
    

36. 36).Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med J 2020; 383:517–525
    
    

37. 37).Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19.A randomized trial. Ann Int Med 2020 Jul 16 : M20–4207
    
    

38. 38).Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial. Clinical Infectious Diseases, ciaa1009, [https://doi.org/10.1093/cid/ciaa1009](https://doi.org/10.1093/cid/ciaa1009) Published: 16 July 2020
    
    

39. 39).Mitjà O, Ubals M, Corbacho-Monné M, et al. A cluster-randomized trial of hydroxychloroquine as prevention of Covid-19 transmission and disease. medRxiv 2020.07.20.20157651; doi: [https://doi.org/10.1101/2020.07.20.20157651](https://doi.org/10.1101/2020.07.20.20157651)
    
    

40. 40).Ferreira A, Oliveira-e-Silva A, Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. J Med Virol 2020:1-5J Med Virol. 2020;1–5 DOI: 10.1002/jmv.26286
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/jmv.26286&link_type=DOI) 

41. 41).Abella BS, Jolkovsky EL, Biney BT, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers. A randomized clinical trial JAMA Intern Med.doi:10.1001/jamainternmed.2020.6319 Published online September 30, 2020.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jamainternmed.2020.6319&link_type=DOI) 

42. 42).Rajasingham R, Bangdiwala AS, Nicol MR, et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. Preprint. medRxiv. 2020;2020.09.18.20197327. Published 2020 Sep 18. doi:10.1101/2020.09.18.20197327
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoibWVkcnhpdiI7czo1OiJyZXNpZCI7czoyMToiMjAyMC4wOS4xOC4yMDE5NzMyN3YxIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMDEvMjMvMjAyMC4wNS4yNy4yMDExNTIzOC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

43. 43).Li Y, Xie Z, Lin W, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI.Med (N Y). 2020 May 19 doi: 10.1016/j.medj.2020.04.001
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.medj.2020.04.001&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32401715&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

44. 44).Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

45. 45).RECOVERY Collaborative Group. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Published Online October 5. 2020 [https://doi.org/10.1016/S0140-6736(20)32013-4](https://doi.org/10.1016/S0140-6736(20)32013-4).
    
    

46. 46).Hung IFN, Lung KC, Tso EYK et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Lancet,2020 May 30;395(10238):1695–1704.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)31042-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32401715&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

47. 47).Estebanez M, Ramirez-Olivencia G, Mata T, et al. Clinical evaluation of IFN beta-1-b in COVID-19 pneumonia: a retrospective study. MedRxiv doi: [https://doi.org/10.1101/2020.05.15.20084293](https://doi.org/10.1101/2020.05.15.20084293)
    
    

48. 48).Pereda R, González D, Rivero HB, et al. Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience. medRxiv preprint doi: [https://doi.org/10.1101/2020.05.29.20109199](https://doi.org/10.1101/2020.05.29.20109199).
    
    

49. 49). PE Idelsis, Perez-Escribano J, Duncan-Robert Y, et al. Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA medRxiv [https://doi.org/10.1101/2020.07.29.20164251](https://doi.org/10.1101/2020.07.29.20164251)
    
    

50. 50).Rahmani H, Davoudi-Monfared E, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020 Nov; 88: 106903. Published online 2020 Aug 24. doi: 10.1016/j.intimp.2020.106903
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.intimp.2020.106903&link_type=DOI) 

51. 51).Meng Z, Wang T, Chen L, et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent COVID-19 in medical staff in an epidemic area. medRxiv. [https://doi.org/10.1101/2020.04.11.20061473](https://doi.org/10.1101/2020.04.11.20061473)
    
    

52. 52).Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 2020 Published OnlineNovember 12, 2020 [https://doi.org/10.1016/S2213-2600(20)30511-7](https://doi.org/10.1016/S2213-2600(20)30511-7)
    
    

53. 53).Xua X, Hanb M, Lia T, et al. Effective treatment of severe COVID-19 patients with tocilizumab 10970–10975. Proc Natl Acad Sci, May 19, 2020, vol. 117, no. 20 [www.pnas.org/cgi/doi/10.1073/pnas.2005615117](http://www.pnas.org/cgi/doi/10.1073/pnas.2005615117)
    
    

54. 54).Somers EC, Eschenauer GA, Troost JP. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. MedRxiv doi: [https://doi.org/10.1101/2020.05.29.20117358](https://doi.org/10.1101/2020.05.29.20117358)
    
    

55. 55).Rossi B,  Nguyen LS, Zimmermann, et al. Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study medRxiv doi: [https://doi.org/10.1101/2020.06.06.20122341](https://doi.org/10.1101/2020.06.06.20122341)
    
    

56. 56).Martinez-Sanz J, Muriel A, l Ron R, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: A Multicenter Cohort Study. MedRxiv doi: [https://doi.org/10.1101/2020.06.08.20125245](https://doi.org/10.1101/2020.06.08.20125245)
    
    

57. 57).Petrak R, Skorodin N, Van Hise N, et al. Tocilizumab as a therapeutic agent for critically ill patients infected with SARS-CoV-2. MedRxiv doi: [https://doi.org/10.1101/2020.06.05.20122622](https://doi.org/10.1101/2020.06.05.20122622)
    
    

58. 58).Perrone P, Piccirillo MC, Ascierto PA, et al. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial. MedRXiv doi: [https://doi.org/10.1101/2020.06.01.20119149](https://doi.org/10.1101/2020.06.01.20119149)
    
    

59. 59).Garcia EM, Caballero VR, Albiach L, et al. Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection medRxiv doi: [https://doi.org/10.1101/2020.06.05.20113738](https://doi.org/10.1101/2020.06.05.20113738)
    
    

60. 60).Wadud N, Ahmed N, Shergil M, et al. Improved survival outcome in SARs-CoV-2 (COVID-19) acute respiratory distress syndrome patients with tocilizumab administration. MedRxiv doi: [https://doi.org/10.1101/2020.05.13.20100081](https://doi.org/10.1101/2020.05.13.20100081)
    
    

61. 61).Sanchez-Montalva A, Selares-Nadal J, Espinosa-Pereiro J, et al. Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study.doi: [https://doi.org/10.1101/2020.05.07.20094599](https://doi.org/10.1101/2020.05.07.20094599)
    
    

62. 62).Ramaswamy M, Mannam P, Comer R, et al. Off-label real world experience using tocilizumab for patients hospitalized with COVID-19 disease in a regional community health system: A case-control study medRxiv. doi: [https://doi.org/10.1101/2020.05.14.20099234](https://doi.org/10.1101/2020.05.14.20099234)
    
    

63. 63).Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020; 2(8): 2, e474–e484
    
    

64. 64).Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020; 2: e325–31
    
    

65. 65).Cauchois R, Koubia M, Delarbreb D, et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc Nat Acad Sci 2020; 117: 18951–18953
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoicG5hcyI7czo1OiJyZXNpZCI7czoxMjoiMTE3LzMyLzE4OTUxIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjEvMDEvMjMvMjAyMC4wNS4yNy4yMDExNTIzOC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

66. 66).Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020; 2: e393–e400
    
    

67. 67).Kyriazopoulou E, Panagopoulos P, Metallidis S, et al. Anakinra to prevent respiratory failure in COVID-19.medRxiv preprint doi: [https://doi.org/10.1101/2020.10.28.20217455](https://doi.org/10.1101/2020.10.28.20217455); this version posted October 29, 2020.
    
    

68. 68).Salvarani C. Dolci G, Massari M et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia JAMA Intern Med. Published online October 20, 2020. doi:10.1001/jamainternmed.2020.6615
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jamainternmed.2020.6615&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33080005&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

69. 69).Rosas IO, Bräu N,, Waters M, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia posted September 12, 2020. medRxiv. [https://doi.org/10.1101/2020.08.27.20183442doi](https://doi.org/10.1101/2020.08.27.20183442doi):
    
    

70. 70).Hermine O, Mariette X, Tharaux PL, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A randomized clinical trial Published Online: October 20, 2020. doi:10.1001/jamainternmed.2020.6820
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jamainternmed.2020.6820&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33080017&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

71. 71).Villar J, Ferrando C, Martínez D et al. Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–276
    
    

72. 72).Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX Randomized Clinical Trial. 2020;324(13):1307–1316.
    
    

73. 73).RECOVERY Collaborative Group. Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. July 17, 2020 DOI: 10.1056/NEJMoa2021436
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2021436&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32678530&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

74. 74).Salton F, Confalonieri P, Santus P, et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. Open Forum Infectious Diseases, Volume 7, Issue 10, October 2020, ofaa421, [https://doi.org/10.1093/ofid/ofaa421](https://doi.org/10.1093/ofid/ofaa421)
    
    

75. 75).Fadel R, Morrison AR, Vahia A, et al. Early short-course corticosteroids in hospitalized patients with COVID-1. Clinical Infectious Diseases 2020; ciaa601, [https://doi.org/10.1093/cid/ciaa601](https://doi.org/10.1093/cid/ciaa601)
    
    

76. 76).Villar J, Confalonieri, M, Pastore, SM, et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by Coronavirus Disease 2019. Crit Care Explor April 2020;2:e0111
    
    

77. 77).Marik PE, Kory P, Varon J, et al. MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale, Expert Review of Anti-infective Therapy [https://doi.org/10.1080/14787210.2020.1808462](https://doi.org/10.1080/14787210.2020.1808462) published on line 18 aug 2020
    
    

78. 78).Chroboczek T, Lacoste L, Wackenheim C, et al. Beneficial effect of corticosteroids in severe COVID-19 pneumonia: a propensity score matching analysis. MedRxiv: doi: [https://doi.org/10.1101/2020.05.08.20094755](https://doi.org/10.1101/2020.05.08.20094755)
    
    

79. 79).Jeronimo CMP, Farias MEL, BSc., Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): A randomised, double-blind, phase iib, placebo-controlled trial. Clinical Infectious Diseases, ciaa1177, [https://doi.org/10.1093/cid/ciaa1177](https://doi.org/10.1093/cid/ciaa1177)
    
    

80. 80).Dequin PF, Heming NMD, Mezian F, et al; Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19, A randomized clinical trial JAMA. 2020;324(13):1298–1306. doi:10.1001/jama.2020.16761
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.16761&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32423584&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

81. 81).Derek C Angus DC, Derde L 3 4, Farah Al-Beidh F. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1317–1329. doi: 10.1001/jama.2020.17022
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.17022&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32778601&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

82. 82).Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020 ;324(5):460–470.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.1004&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

83. 83).Perotti C, Baldanti F, Bruno R, et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. Haematologica. 2020 Jul 23;haematol.2020.261784. doi: 10.3324/haematol.2020.261784
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiaGFlbWF0b2wiO3M6NToicmVzaWQiO3M6MjI6ImhhZW1hdG9sLjIwMjAuMjYxNzg0djEiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMS8wMS8yMy8yMDIwLjA1LjI3LjIwMTE1MjM4LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

84. 84).Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, et al. Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial. MedRxiv September 1, 2020. [https://doi.org/10.1101/2020.08.26.20182444doi](https://doi.org/10.1101/2020.08.26.20182444doi):
    
    

85. 85).Rogers R, Shehadeh F, Mylona E, et al. Convalescent plasma for patients with severe COVID-19: a matched cohort study medRxiv 2020.08.18.20177402; doi: [https://doi.org/10.1101/2020.08.18.20177402](https://doi.org/10.1101/2020.08.18.20177402)
    
    

86. 86).Joyner MJ, Klassen SA, Senefeld JW, et al. Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. MedRxiv posted August 28, 2020. [https://doi.org/10.1101/2020.07.29.20162917](https://doi.org/10.1101/2020.07.29.20162917) doi: medRxiv pr
    
    

87. 87).Joyner MJ, Bruno KA, Klassen SA, et al., Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients Mayo Clin Proc. 2020;95(9):1888–1897
    
    

88. 88).Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) BMJ 2020;371:m3939 [http://dx.doi.org/10.1136/bmj.m3939](http://dx.doi.org/10.1136/bmj.m3939)
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MzoiYm1qIjtzOjU6InJlc2lkIjtzOjE3OiIzNzEvb2N0MjJfOC9tMzkzOSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIxLzAxLzIzLzIwMjAuMDUuMjcuMjAxMTUyMzguYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

89. 89).Chen P, Nirula A, Heller B et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19 October 28, 2020, at NEJM.org. DOI: 10.1056/NEJMoa2029849
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2029849&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33113295&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

90. 90).Freedberg DE, Conigliaro J, Sobieszczyk ME, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterology. 2020 May 22 doi: 10.1053/j.gastro.2020.05.053 [Epub ahead of print]
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1053/j.gastro.2020.05.053&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32446698&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

91. 91).Deftereos SG, Giannopoulos G, Dimitrios A, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with Coronavirus Disease 2019. The GRECCO-19 randomized clinical trial. JAMA Network Open. 2020;3:e2013136.
    
    

92. 92).Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial medRxiv 2020.10.21.20217208; doi: [https://doi.org/10.1101/2020.10.21.20217208](https://doi.org/10.1101/2020.10.21.20217208)
    
    

93. 93).Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19. A randomized clinical trial. JAMA. Published online November 12, 2020. doi:10.1001/jama.2020.22760
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.22760&link_type=DOI) 

94. 94).Behera P, Patro BK, Singh AK, et al. Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study medRxiv 2020.10.29.20222661; doi: [https://doi.org/10.1101/2020.10.29.20222661](https://doi.org/10.1101/2020.10.29.20222661)
    
    

95. 95).Khan MSI, Khan MSI, Debnath CR, et al. Ivermectin treatment may improve the prognosis of patients with COVID-19. Archivos de Bronconeumología. 2020
    
    

96. 96).Shouman W. [https://ClinicalTrials.gov/show/NCT04422561](https://ClinicalTrials.gov/show/NCT04422561) Results posted 27 Aug 20
    
    

97. 97).Rajter JC, Sherman M, Fatteh N, et al. ICON (Ivermectin in COvid Nineteen) study: Use of ivermectin is associated with lower mortality in hospitalized patients with COVID19. medRxiv doi: [https://doi.org/10.1101/2020.06.06.20124461](https://doi.org/10.1101/2020.06.06.20124461)
    
    

98. 98).Shi L, Huang H, Lu X, et al. Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo-controlled phase 2 trial. medRxiv 2020.10.15.20213553; doi: [https://doi.org/10.1101/2020.10.15.20213553](https://doi.org/10.1101/2020.10.15.20213553)
    
    

99. 99).Folegatti PM,  J Ewer KJ, Parvinder K Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 ;396(10249):467–478
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/s0140-6736(20)31604-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32702298&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

100.100).Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 —preliminary report N Engl J Med. 2020 Jul 14;NEJMoa2022483. doi: 10.1056/NEJMoa2022483
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2022483&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32663912&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

101.101).Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo controlled, phase 2 trial. Lancet 2020; 395(10240):, P1845–1854, June 13, 2020
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736-(20)-31208-3&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

102.102).Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New Engl J Med. DOI: 10.1056/NEJMoa2026920
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2026920&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32877576&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

103.103).Xia S, Duan K, Yuntao Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes. Interim analysis of 2 randomized clinical trials. JAMA 2020;e2015543. doi: 10.1001/jama.2020.15543
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2020.15543&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=32789505&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

104.104).Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. Published online September 4, 2020 [https://doi.org/10.1016/S0140-6736(20)31866-31](https://doi.org/10.1016/S0140-6736(20)31866-31)
    
    

105.105).Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. [published online ahead of print August 12, 2020] Nature 2020
    
    

106.106).Liu M, Thomadsen R, Yao S. Forecasting the spread of COVID-19 under different reopening strategies. Nature Scientific Reports (In Press)
    
    

107.107).Institute for Health Metrics and Evaluation. COVID-9 projections. Covid 19.healthdata.org
    
    

108.108).Marik PE, Varon J, Kory P. Treatment of Covid-19 is critically phase specific. Crit Care Shock 2020;23 :10–12
    
    

109.109).Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol 2020;94:e02015–19.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1128/jvi.02015-19&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31826992&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

110.110).Fatima K, Syed NI. Dengvaxia controversy: impact on vaccine hesitancy. J Glob Health. 2018; 8(2): 020312.
    
    

111.111).Edridge AWD, Kaczorowska J, Hoste ACR et al. Coronavirus protective immunity is short-lasting.medRxiv preprint doi: [https://doi.org/10.1101/2020.05.11.20086439](https://doi.org/10.1101/2020.05.11.20086439). this version posted June 16, 2020.
    
    

112.112).Flu Vaccination Coverage, United States, 2019–20 Influenza Season. FluVaxView webpage report posted online October 1, 2020 [https://www.cdc.gov/flu/fluvaxview/coverage-1920estimates.htm](https://www.cdc.gov/flu/fluvaxview/coverage-1920estimates.htm)
    
    

113.113).Zimmermann P, Nigel C. Coronavirus infections in children including COVID-19. An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. The Pediatric Infectious Disease Journal 2020;39 : 355–368
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/INF.0000000000002660&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 

114.114).Sepkowitz KA. AIDS-The first 20 years. N Engl J Med 2001; 344 (23):1764–1772
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJM200106073442306&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=11396444&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000169133600006&link_type=ISI) 

115.115).Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010; 85(1): 1–18
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.antiviral.2009.10.002&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20018391&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2021%2F01%2F23%2F2020.05.27.20115238.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000274978200001&link_type=ISI) 

116.116).Fauci AS. Preface: Evolving ethical issues over the course of the AIDS pandemic. Public Health Rev 34, 2 (2012)
    
    

117.117).Harris NS, Johnson AS, Huang YA, et al. Vital Signs: Status of human immunodeficiency virus testing, viral suppression, and HIV pre-exposure prophylaxis - United States, 2013-2018. MMWR Morb Mortal Wkly Rep. 2019; 68(11):1117–1123